Riboflavin, Folic Acid and Zinc: study protocols
4 study groups took Riboflavin together with Folic Acid and Zinc. These are the doses the studies gave. They are not a recommendation.
Fewer than 5 study groups in one unit match, too few to draw the chart.
Commonly used together
4 of 4 study groups took Riboflavin, Folic Acid and Zinc with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 4 |
| Vitamin B6 | 4 |
| Iron | 3 |
| Vitamin D | 3 |
4 study groups
| Study | |||||
|---|---|---|---|---|---|
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 1.8 mg | 400 mcg | 30 mg | — | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 1.8 mg | 400 mcg | 10 mg | — | 870 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · UNIMMAP tablet · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 1.4 mg | 400 mcg | 15 mg | 12 weeks | 105 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 2.4 mg | 400 mcg | 12.5 mg | 60 days | 52 |